secwatch.observer — SEC 8-K summary
======================================

Issuer:     Mirum Pharmaceuticals, Inc. (MIRM)
CIK:        0001759425
Form:       8-K
Filed at:   2024-05-31T23:59:59+00:00
Accession:  0001193125-24-151965
Event type: regulatory
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Mirum's LIVMARLI gets positive CHMP opinion for PFIC; EC decision in Q3 2024
----------------------------------------------------------------------------

- CHMP adopted positive opinion for LIVMARLI (maralixibat) to treat PFIC in patients aged 3 months and older.
- CHMP concluded LIVMARLI provides significant clinical benefit vs already-approved PFIC treatment.
- COMP recommended maintaining Orphan Drug Designation for LIVMARLI in PFIC.
- European Commission decision on marketing authorization expected in Q3 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1759425/000119312524151965/0001193125-24-151965-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1759425/000119312524151965/d825353d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-151965

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer